about
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPrevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology groupPrevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutationsLeukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology GroupResidual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group.The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
P50
Q24602856-672BC1F7-2E20-45A6-8281-7AE8C3290893Q33754603-780BA1D0-96AF-429C-AE4F-7C2155DB02C8Q33990843-3E5EFFD0-27B8-4E74-ADB6-211EC6628F98Q34052581-A6AD6BAC-A44D-403E-B0F0-6C024691A44AQ34541735-077E9C80-1160-4079-9383-70F52204373FQ35046171-28428AE7-DFF1-4A60-9250-79B044BFE868Q36194222-53039282-53AC-496E-BF4F-2ADD4F521F5AQ37125803-38321B81-CE2E-4DBB-9B65-58B4CA536E7DQ41755821-B4432575-E733-4885-B1FE-74D069DF3A49Q45012427-9802F1E7-D6DE-4597-8607-A42835A0D81EQ47563820-DA09DB8A-203E-4D99-8016-B2119B2F77DB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Phoenix A Ho
@ast
Phoenix A Ho
@en
Phoenix A Ho
@es
Phoenix A Ho
@nl
Phoenix A Ho
@sl
type
label
Phoenix A Ho
@ast
Phoenix A Ho
@en
Phoenix A Ho
@es
Phoenix A Ho
@nl
Phoenix A Ho
@sl
prefLabel
Phoenix A Ho
@ast
Phoenix A Ho
@en
Phoenix A Ho
@es
Phoenix A Ho
@nl
Phoenix A Ho
@sl
P106
P31
P496
0000-0003-3786-7583